SB 1179 Summary

• Prohibits manufacturers, wholesalers, and wholesale distributor-brokers from denying, restricting, or conditioning the acquisition of 340B drugs by eligible 340B entities or their contracted pharmacies, with exceptions for conduct authorized by state or federal law.

• Requires 340B entities to submit annual reports to the Department of Health and Human Services beginning July 1, 2026, including recertification documents, community health needs assessments, compliance affidavits, audit descriptions, and program impact documentation.

• Mandates manufacturers to report annually on prescription drugs exceeding $40.00 per course of treatment that experienced more than 15% wholesale acquisition cost increases in the prior 12 months, including production costs, patent expiration dates, and dosage forms.

• Requires the Department of Health and Human Services to post all submitted reports on its publicly accessible website.

• Takes effect only if Senate Bill No. 952 of the 102nd Legislature is enacted into law.